1.1Phenyl terminal group
A single bond joins the phenyl ring to the scaffold at R1. The planar aromatic ring presents a hydrophobic face and fixes the relative positions of its ring carbons.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A single bond joins the phenyl ring to the scaffold at R1. The planar aromatic ring presents a hydrophobic face and fixes the relative positions of its ring carbons.
The ring bonds directly to the carbonyl carbon of a primary carboxamide. The carbonyl oxygen accepts a hydrogen bond, and the amide nitrogen donates one.
A methylene group extends from each side of the shared carbon, and an oxygen joins the two methylene groups. The resulting ring constrains the two attachment vectors and presents an ether oxygen as a hydrogen-bond acceptor.
The carbon–carbon double bond fixes the two carbons and their directly bonded neighbors in one plane. The π bond restricts rotation about that connection.
One methylene group bonds to two adjacent pyrrolidine carbons to form a fused cyclopropane. The shared carbon–carbon edge constrains the geometry at both fusion atoms while retaining the pyrrolidine nitrogen.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An amorphous dispersion of the inhibitor in its free form replaces the salt form in an oral dosage formulation. The free form and hydroxypropyl methylcellulose acetate succinate are dissolved in a common solvent and spray-dried to form a powder. Powder X-ray diffraction checks for crystalline material, and liquid chromatography measures drug release in a dissolution test.
A paddle dissolution apparatus holds identical inhibitor tablets in separate vessels containing 900 mL of the same dissolution medium at 37 °C. One set of paddles rotates at 50 rpm and a second set rotates at 75 rpm. Samples taken at 5, 15, 30, and 60 minutes are filtered and assayed by liquid chromatography to compare release profiles.
Solid inhibitor doses are sealed individually in aluminum laminate blister cavities. The blister cards are enclosed in a sealed secondary pouch with a humidity indicator card visible through a clear barrier window. The indicator records moisture exposure within the pouch, and tablets from a matched stability sample are assayed for drug content and degradation products.
A confocal Raman microscope maps a dry-polished cross section of a compressed inhibitor tablet. The instrument collects reference spectra from the inhibitor solid forms and the excipients, then acquires spectra on a grid across the cross section. Software matches each grid spectrum to the references and plots the locations of the identified solid forms.
A liquid chromatography system analyzes formulation samples alongside a reference solution and a formulation blank. Software aligns peaks against reference retention times, integrates peak areas, and calculates concentrations for degradation products with calibration curves. The software flags unresolved peaks and reports their retention times and areas for review.
A six-membered terminal ring contains ether oxygens at positions 1 and 4. Both oxygens act as hydrogen-bond acceptors, and the ring fixes their spacing along the bond network.
Set p to 2. In the R1 arrangement indexed by p, place an RA group at each of two distinct positions.
Set m to 1 in the R10-bearing arrangement. One position carries an R10 group.
Use methoxy, —OCH3, for R11. The oxygen bonds directly to the framework and to a single methyl carbon.
Set R3 to fluorine, R4 to hydroxyl, and R5 to hydrogen. The hydroxyl provides a hydrogen-bond donor and acceptor at the R4 position.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
X is selected from C3-C8 alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;A · US 8,466,148 B2 · ¶ 14
X is selected from C3-C8 alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;B · US 8,933,074 B2 · ¶ 13
In an additional embodiment, Z is selected from benzimidazolyl, quinolinyl, tetrahydroquinolyl, imidazo[1,2-a]pyridin-2-yl, tetrahydroisoquinolyl, 5-methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl, 6-fluoroquinolyl and isoquinolinyl, all of which may be optionally substituted with up to 3 substituents independently selected from alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl and cyano and nitro.A · US 8,466,148 B2 · ¶ 176
In an additional embodiment, Z is selected from benzimidazolyl, quinolinyl, tetrahydroquinolyl, imidazo[1,2-a]pyridin-2-yl, tetrahydroisoquinolyl, 5-methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl, 6-fluoroquinolyl and isoquinolinyl, all of which may be optionally substituted with up to 3 substituents independently selected from alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl and cyano and nitro.B · US 8,933,074 B2 · ¶ 168
In an additional embodiment, Z is selected from benzimidazolyl, quinolinyl, tetrahydroquinolyl, imidazo[1,2-a]pyridin-2-yl, tetrahydroisoquinolyl, 5-methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl, 6-fluoroquinolyl and isoquinolinyl, all of which may be optionally substituted with up to 3 substituents independently selected from alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl and cyano and nitro.A · US 8,466,148 B2 · ¶ 176
In an additional embodiment, Z is selected from benzimidazolyl, quinolinyl, tetrahydroquinolyl, imidazo[1,2-a]pyridin-2-yl, tetrahydroisoquinolyl, 5-methylpyridin-2-yl, 3,5-dimethylpyridin-2-yl, 6-fluoroquinolyl and isoquinolinyl, all of which may be optionally substituted with up to 3 substituents independently selected from alkyl, alkoxy, cycloalkyl, cycloalkyloxy, cycloalkylalkyl, cycloalkylalkoxy, halogen, alkylsulfonyl and cyano and nitro.B · US 8,933,074 B2 · ¶ 168
R3 and R4 are independently selected from C1-C4 alkyl, CF3, optionally substituted cycloalkyl, or R3 and R4 taken together form a 3-6 membered cycloalkyl ring;A · US 8,466,148 B2 · ¶ 14
R3 and R4 are independently selected from C1-C4 alkyl, CF3, optionally substituted cycloalkyl; or R3 and R4 taken together form a 3-6 membered cycloalkyl ring;B · US 8,933,074 B2 · ¶ 13
R3 and R4 are independently selected from C1-C4 alkyl, CF3, optionally substituted cycloalkyl, or R3 and R4 taken together form a 3-6 membered cycloalkyl ring;A · US 8,466,148 B2 · ¶ 14
R3 and R4 are independently selected from C1-C4 alkyl, CF3, optionally substituted cycloalkyl; or R3 and R4 taken together form a 3-6 membered cycloalkyl ring;B · US 8,933,074 B2 · ¶ 13
R5 is selected from alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl and optionally substituted alkoxyalkyl; n is independently selected from 1 and 2;A · US 8,466,148 B2 · ¶ 14
R5 is selected from alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl and optionally substituted alkoxyalkyl; n is independently selected from 1 and 2; R7 is selected from hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl and optionally substituted alkoxyalkyl;B · US 8,933,074 B2 · ¶ 13
An empty cell means only that no passage was reproduced there.
The disclosure also relates to methods for treating neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.A · US 8,466,148 B2 · ¶ 2
This experiment lends support to the use of a PDE10 inhibitor as an antipsychotic since similar trends are seen with known, marketed antipsychotics.A · US 8,466,148 B2 · ¶ 8
The disclosure also relates to methods for treating neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.B · US 8,933,074 B2 · ¶ 2
This experiment lends support to the use of a PDE10 inhibitor as an antipsychotic since similar trends are seen with known, marketed antipsychotics.B · US 8,933,074 B2 · ¶ 8
patent.fyi, US 2026/0355212 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355212/, SHA-256 de486745bcaa7bbd4094f45fc24ebe42095b5206ae3e7640d23ed194d6054eb3